StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a research report sent to investors on Wednesday morning. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reaffirmed a buy rating and set a $4.25 price objective on shares of OncoCyte in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of Hold and a consensus price target of $4.06.

OncoCyte Price Performance

OCX stock opened at $3.14 on Wednesday. OncoCyte has a 12 month low of $2.08 and a 12 month high of $4.34. The firm has a 50 day moving average of $3.08 and a two-hundred day moving average of $2.92.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.